David T. Winn
Ohio State University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David T. Winn.
Bioorganic & Medicinal Chemistry Letters | 1999
James P. Edwards; Robert I. Higuchi; David T. Winn; Charlotte L. F. Pooley; Thomas R. Caferro; Lawrence G. Hamann; Lin Zhi; Keith B. Marschke; Mark E. Goldman; Todd K. Jones
A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone.
Bioorganic & Medicinal Chemistry Letters | 1998
Lawrence G. Hamann; David T. Winn; Charlotte L. F. Pooley; Christopher M. Tegley; Sarah J. West; Luc J. Farmer; Lin Zhi; James P. Edwards; Keith B. Marschke; Dale E. Mais; Mark E. Goldman; Todd K. Jones
A series of nonsteroidal human progesterone receptor (hPR) antagonists based on conformationally-restricted analogues of a 6-aryl-1,2-dihydro-2,2,4-trimethylquinoline pharmacophore were synthesized and evaluated for their ability to bind to the human progesterone receptor and inhibit progesterone-stimulated reporter gene expression in mammalian cells.
Bioorganic & Medicinal Chemistry Letters | 2009
Amogh Boloor; Denise Hanway; Maria Joshi; David T. Winn; Gabriel Mendez; Marlena Walls; Ping Wei; Fuxin Qian; Xiaoli Zhang; Yuliang Zhang; Michael Hepperle; Xinqiang Li; David Alan Campbell; Juan Manuel Betancort
A new series of NS3/4A protease boronic acid inhibitors is described. The compounds show good biochemical potency and cellular activity. The peptidomimetic inhibitors were evaluated against proteases from different HCV genotypes and clinically relevant NS3/4A mutants. Compound 28 displayed subnanomolar to single digit nanomolar potencies in the enzymatic assays and an EC50 of 25 nM in the replicon cell-based assay.
Bioorganic & Medicinal Chemistry Letters | 1994
Mark A. Mortellaro; Sungyeap Hong; David T. Winn; Anthony W. Czarnik
Abstract The primary- and secondary-side oxime derivatives of β-cyclodextrin have been prepared as hydrolysis reagents. The secondary-side derivative has been converted to the first secondary-side keto-cyclodextrin.
Bioorganic & Medicinal Chemistry Letters | 2009
Juan Manuel Betancort; David T. Winn; Ruzhang Liu; Quansheng Xu; Junjuan Liu; Wensheng Liao; Shuhui Chen; David Carney; Denise Hanway; James Schmeits; Xinqiang Li; Eric M. Gordon; David Alan Campbell
The synthesis and biochemical evaluation of novel cyanothiazolidine inhibitors of dipeptidyl peptidase 4 (DPP4) is described. Their main structural feature is a constrained bicyclic core that prevents the intramolecular formation of inactive cyclic species. The inhibitors show good to moderate biochemical potency against DPP4 and display distinct selectivity profiles towards DPP7, DPP8 and DPP9 depending on their substitution.
Archive | 1995
Todd K. Jones; Mark E. Goldman; Charlotte L. F. Pooley; David T. Winn; James P. Edwards; Sarah J. West; Christopher M. Tegley; Lin Zhi; Lawrence G. Hamann; Luc J. Farmer; Robert L. Davis
Archive | 1995
Todd K. Jones; David T. Winn; Mark E. Goldman; Lawrence G. Hamann; Lin Zhi; Luc J. Farmer; Robert L. Davis
Proceedings of the National Academy of Sciences of the United States of America | 2005
Eric Okerberg; Jiangyue Wu; Baohong Zhang; Babak Samii; Kelly Blackford; David T. Winn; Kevin Shreder; Jonathan J. Burbaum; Matthew P. Patricelli
Archive | 2004
David Alan Campbell; David T. Winn; Juan Manuel Betancort
Archive | 2008
David Alan Campbell; Michael Hepperle; David T. Winn; Juan Manuel Betancort